Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
04:30pm, Monday, 08'th Dec 2025
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025.
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
02:56pm, Monday, 08'th Dec 2025
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
The Generational Shift I See Now - And My 33 Stocks For What's Coming
07:30am, Sunday, 07'th Dec 2025
I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and at
Do These 3 Healthcare Stocks Need a Checkup?
04:05pm, Friday, 05'th Dec 2025
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
10:46am, Friday, 05'th Dec 2025
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval
08:36am, Friday, 05'th Dec 2025
FDA approves Breyanzi, a CAR T cell therapy for relapsed or refractory marginal zone lymphoma. It has a high response rate.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
05:38pm, Thursday, 04'th Dec 2025
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
BMY Gains on News of Continuation of Alzheimer's Disease Study
11:31am, Thursday, 04'th Dec 2025
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.
02:05pm, Wednesday, 03'rd Dec 2025
Bristol Myers' stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer's treatment, even though the outcome of a late-stage trial has been delayed.
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities
01:51pm, Wednesday, 03'rd Dec 2025
Bristol Myers Squibb & Co. (NYSE: BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
11:00am, Wednesday, 03'rd Dec 2025
LOS ANGELES--(BUSINESS WIRE)-- #biotech--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Wednesday, 03'rd Dec 2025
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb Stock Climbs on Alzheimer's Trial Update. What to Know.
09:16am, Wednesday, 03'rd Dec 2025
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer's disease.
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
06:59am, Wednesday, 03'rd Dec 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease.
